Efficacy of Hyoscine-n-butylbromide in Catheter-related Bladder Discomfort After Elective Cesarean Section.

• Status: Unknown status
• Trial end date: 2018-07-15
• Target enrollment: 0
• Participant gender: Female

Summary

a prospective, randomized, placebo-controlled study will be conducted to investigate whether hyoscine-n-butylbromide has preventive effects on early postoperative CRBD in patients with urinary catheters who will undergo elective cesarean sections.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Cairo University
• Treatments: Butylscopolammonium Bromide; Scopolamine; Scopolamine Hydrobromide

Criteria

Inclusion Criteria:

• Elective primary or repeat cesarean section more than 37 weeks of gestation scheduled to insert a Foley catheter in the operation site.

• The absence of significant vaginal bleeding

Exclusion Criteria:

• • Urinary infection (assessed clinically and by urinalysis of midstream sample of urine (MSSU) with chemical indicator strips or dipsticks).

• Contraindications for general anesthesia.

• Maternal bladder, urethral and renal disorders causing irritating voiding problems such as dysuria, urge and stress incontinence.

• Obstructive voiding symptoms like incomplete emptying, straining and voiding difficulty before surgery.

• Overactive bladder (frequency: more than three times during the night or more than eight times in 24 h).

• Morbid obesity.

• Disturbances of the central nervous system (epilepsy, patients receiving MAO inhibitor).

• Hypertensive disorders and/ or systemic disease requiring particular patient care (for example, cardiac disease, nephritic disorders).

• Chronic analgesic abuse.

• Hepatic or psychiatric disease will be excluded from the study.

• A history of hypersensitivity or contraindication to hyoscine-n-butylbromide.